Rekombinanter PDCD1 (Spartalizumab Biosimilar) Antikörper

Produktnummer ABIN7200669

Der Maus Monoklonal Anti-PDCD1 (Spartalizumab Biosimilar)-Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, PDCD1 (Spartalizumab Biosimilar) in Proben von Human zu detektieren.

Kurzübersicht für Rekombinanter PDCD1 (Spartalizumab Biosimilar) Antikörper (ABIN7200669)

Target: PDCD1 (Spartalizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser PDCD1 (Spartalizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Produktdetails anti-PDCD1 (Spartalizumab Biosimilar) Antikörper

Verwendungszweck: Spartalizumab Biosimilar, Human PD-1 Monoclonal Antibody

Spezifität: The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.

Produktmerkmale: Recombinant Humanized IgG4 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.

Isotyp: IgG4 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu PDCD1 (Spartalizumab Biosimilar)

Target: PDCD1 (Spartalizumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.